跳至主要内容
临床试验/NCT03116412
NCT03116412招募中不适用

A Prospective Randomized Multicenter Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of Stage IIb-c and III Cutaneous Malignant Melanoma

Uppsala University28 个研究点 分布在 1 个国家目标入组 1,300 人开始时间: 2017年6月8日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
1,300
试验地点
28
主要终点
Overall survival

研究概览

简要总结

It is not known whether radiological assessments during follow up after surgery for high risk melanoma improve survival. Since radiological examinations are resource demanding, could inflict worry and cause irradiation exposure it is an important question to address. With the introduction of effective medical treatments for malignant melanoma patients, there is a tendency to introduce radiological assessments despite the lack of evidence.

详细描述

The patients are randomized 1:1 to routine follow up for 3 years with regular doctors´ appointments according to national guidelines and the same follow up but with the addition of whole body CT or Positron Emission Tomography (PET) scans and blood tests. An interim analysis will be conducted when 1000 patients have been included.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • At least 18 years of age.
  • Radical surgery for Cutaneous Malignant Melanoma (CMM) stage IIb-c and III.
  • Sufficient renal function for i.v. contrast scannings.

排除标准

  • The patient is assessed as unfit to receive treatment in the case of recurrence.
  • Life-expectancy less than 2 years due to concurrent disease (e.g., cardiac disease, terminal multiple sclerosis, liver cirrhosis).
  • Inability to provide informed consent or refusal to do so.
  • Inability to comply with the control or intense follow-up program.
  • Participation in other clinical trials interfering with the control-program.
  • Existing or previous malignancies within the past 5 years (except for in situ breast and cervical cancer, melanoma in situ and non-melanoma skin cancer).
  • Pregnancy or currently planned pregnancy.

结局指标

主要结局

Overall survival

时间窗: At 5 years

Measured from date of inclusion

次要结局

  • Quality of life/QLQ30(During the 3 year intervention period)
  • Quality of life/HAD(During the 3 year intervention period)

研究者

发起方
Uppsala University
申办方类型
Other
责任方
Sponsor

研究点 (28)

Loading locations...

相似试验